Mendel A, et al. - Between 2000 and 2017, researchers estimated 927 females to examine the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and their associated factors. They observed aPL (52%), hypertension (34%) and migraine with aura (22%) as the most common contraindications. They found that females with one or more contraindication were slightly less likely to be taking CHCs as compared to women with no contraindications. They noticed more than half of CHC users with at least one viable contraindication.